<DOC>
	<DOCNO>NCT00000836</DOCNO>
	<brief_summary>To compare safety efficacy sevirumab ( MSL 109 ; Protovir ) , human anti-cytomegalovirus ( CMV ) monoclonal antibody , plus active primary treatment versus placebo plus active primary treatment AIDS patient newly diagnose relapse CMV retinitis . Ganciclovir foscarnet use treatment CMV retinitis , cause hematologic toxicity nephrotoxicity , respectively . Despite continued maintenance therapy drug , relapse occur 85 percent patient within 4 month . Studies suggest MSL 109 , human monoclonal antibody , give either ganciclovir foscarnet , may increase initial response prolong time progression patient CMV retinitis .</brief_summary>
	<brief_title>A Phase II/III Trial Human Anti-CMV Monoclonal Antibody MSL 109 ( MACRT )</brief_title>
	<detailed_description>Ganciclovir foscarnet use treatment CMV retinitis , cause hematologic toxicity nephrotoxicity , respectively . Despite continued maintenance therapy drug , relapse occur 85 percent patient within 4 month . Studies suggest MSL 109 , human monoclonal antibody , give either ganciclovir foscarnet , may increase initial response prolong time progression patient CMV retinitis . Patients randomize receive either MSL 109 placebo every 2 week supplemental therapy primary CMV treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Primary CMV treatment . Patients must : AIDS . Active CMV retinitis . At least one photographable lesion onequarter optic disc area size . Undergoing primary treatment CMV retinitis contraindicate MSL 109 . Visual acuity least one eye 3 letter Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart 1 meter distance ( Snellen equivalent 5/200 ) . Note : Exceptions may make visual acuity impairment possibly reversible least light perception eye . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Retinal detachment schedule surgical repair . Media opacity precludes visualization fundus . Active medical problem sufficient hinder study compliance . Concurrent Medication : Excluded : IVIG . CMV immune globulin ( CMVIG ) . Interferon alpha . Interferon gamma . Interleukin2 ( IL2 ) . Drug alcohol abuse sufficient hinder study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Cytomegalovirus Retinitis</keyword>
</DOC>